紫杉醇联合奈达铂治疗晚期食管癌的临床观察  

Clinical study of paclitaxel combined with nedaplatin in the treatment of advanced esophageal cancer

作　　者：张素芳[1] 常万里 韩太山 张玉芳[1] 王建正[1] 

机构地区：[1]安阳肿瘤医院,河南安阳455000 [2]安阳151医院,河南安阳455000

出　　处：《现代肿瘤医学》2010年第1期94-96,共3页Journal of Modern Oncology

摘　　要：目的:观察紫杉醇(PTX)联合奈达铂(NDP)治疗晚期食管癌的临床疗效和不良反应。方法:晚期食管癌患者51例,紫杉醇135-175mg/m2,静脉滴注,第1天;奈达铂80-100mg/m2,加入生理盐水500ml中静滴2h,第2天;21天为1周期,连用2个周期后评价疗效。结果:全组50例可评价疗效,总有效率58.0%(29/50),完全缓解3例,部分缓解26例,中位生存期为9.8个月,中位疾病进展时间5.7个月,中位缓解时间4.5个月。主要不良反应为骨髓抑制所致的血小板及白细胞减少,消化道反应轻,未发现肝肾功能损害。结论:紫杉醇联合奈达铂治疗晚期食管癌近期疗效高,安全性较好,患者可耐受,值得临床观察应用。Objective：To evaluate the efficiency and toxicity of combined chemotherapy with paclitaxel,nedaplatin in the treatment of advanced esophageal cancer. Methods：Thirty five cases were treated with TPF regimen,PTX 135 - 175mg/m^2,iv, dI ; NDP 80 - 100mg/m^2, iv, d2. The cycle was repeated every 21 days. Results ： The overall response rate was 60.0% （21/35） ,with CR 5.7% （2/35）, PR 54.3% （19/35）. The median survival was 9.7 months （3.5 -22 months） ,the median time to progress was 4.6 months（3 -7 months）. The major toxicity and side effects were myelosuppression and thrombocytopenia, nausea and vomiting, which were mild to moderate. Conclusion：TPF is effective for advanced esophageal cancer and the toxicity and side effects are tolerable.

关 键 词：紫杉醇 奈达铂 食管癌 联合化疗 

分 类 号：R735.1[医药卫生—肿瘤]